MA49127B1 - Dérivés d'indole n-substitués - Google Patents

Dérivés d'indole n-substitués

Info

Publication number
MA49127B1
MA49127B1 MA49127A MA49127A MA49127B1 MA 49127 B1 MA49127 B1 MA 49127B1 MA 49127 A MA49127 A MA 49127A MA 49127 A MA49127 A MA 49127A MA 49127 B1 MA49127 B1 MA 49127B1
Authority
MA
Morocco
Prior art keywords
indole derivatives
substituted indole
formula
derivatives
pharmaceuticals
Prior art date
Application number
MA49127A
Other languages
English (en)
French (fr)
Other versions
MA49127A (fr
Inventor
Thierry Sifferlen
Heinz Fretz
Julien Pothier
Isabelle Lyothier
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA49127A publication Critical patent/MA49127A/fr
Publication of MA49127B1 publication Critical patent/MA49127B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49127A 2017-05-18 2018-05-17 Dérivés d'indole n-substitués MA49127B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (2)

Publication Number Publication Date
MA49127A MA49127A (fr) 2021-05-26
MA49127B1 true MA49127B1 (fr) 2022-05-31

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49127A MA49127B1 (fr) 2017-05-18 2018-05-17 Dérivés d'indole n-substitués

Country Status (32)

Country Link
US (2) US20200069686A1 (enExample)
EP (1) EP3625224B1 (enExample)
JP (1) JP7065117B2 (enExample)
KR (1) KR102650756B1 (enExample)
CN (1) CN110621666A (enExample)
AR (1) AR111806A1 (enExample)
AU (1) AU2018269667B2 (enExample)
BR (1) BR112019024114A2 (enExample)
CA (1) CA3063637A1 (enExample)
CL (1) CL2019003257A1 (enExample)
CO (1) CO2019010804A2 (enExample)
CR (1) CR20190567A (enExample)
CY (1) CY1124528T1 (enExample)
DK (1) DK3625224T3 (enExample)
EA (1) EA039630B1 (enExample)
ES (1) ES2894124T3 (enExample)
HR (1) HRP20211532T1 (enExample)
HU (1) HUE056406T2 (enExample)
IL (1) IL270616B (enExample)
LT (1) LT3625224T (enExample)
MA (1) MA49127B1 (enExample)
MX (1) MX394108B (enExample)
PE (1) PE20191787A1 (enExample)
PH (1) PH12019502562B1 (enExample)
PL (1) PL3625224T3 (enExample)
PT (1) PT3625224T (enExample)
RS (1) RS62441B1 (enExample)
SG (1) SG11201908660RA (enExample)
SI (1) SI3625224T1 (enExample)
TW (1) TWI768043B (enExample)
UA (1) UA124748C2 (enExample)
WO (1) WO2018210995A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
CA3063632A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1267867B1 (en) 2000-03-24 2008-05-14 Asterand Uk Limited Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
EP1506220A1 (en) 2002-05-23 2005-02-16 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
DE602004013938D1 (de) 2003-01-29 2008-07-03 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
PE20050347A1 (es) * 2003-08-26 2005-05-04 Teijin Pharma Ltd Derivados de pirrolopirimidina
AU2004268839A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ES2327760T3 (es) 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
KR20070006891A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
AU2008232265B2 (en) 2007-03-26 2013-02-28 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
CA2681861A1 (en) 2007-03-26 2008-10-16 Astellas Pharma Inc. Ornithine derivative
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
DK2565191T3 (da) 2008-05-14 2014-11-10 Astellas Pharma Inc 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US9029414B2 (en) 2008-09-19 2015-05-12 Biotechnology Research Corporation Triterpenoid compounds and methods of use thereof
MX2011003166A (es) 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
JP5956448B2 (ja) 2010-09-21 2016-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US9175080B2 (en) 2010-09-29 2015-11-03 Nb Health Laboratory Co., Ltd. Antibody against human prostaglandin E2 receptor EP4
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
DK2688883T3 (en) * 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
LT2841428T (lt) 2012-04-24 2018-12-10 Vertex Pharmaceuticals Incorporated Dnr-pk inhibitoriai
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
LT3009426T (lt) 2013-06-12 2018-07-25 Kaken Pharmaceutical Co., Ltd. 4-alkinilimidazolo darinys ir jį, kaip veiklųjį ingredientą, apimantis vaistas
CA2923184A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
HUE048874T2 (hu) 2013-09-06 2020-08-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazol-származékok, mint immunmodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2015058031A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
EA028675B1 (ru) 2013-12-17 2017-12-29 Эли Лилли Энд Компани Соединения диметилбензойной кислоты
SI3083562T1 (sl) 2013-12-17 2017-11-30 Eli Lilly And Company Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2015179615A1 (en) 2014-05-23 2015-11-26 Eisai R&D Management Co., Ltd Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3778562A1 (en) 2015-01-09 2021-02-17 ONO Pharmaceutical Co., Ltd. Tricyclic spiro compound
CN108368127B (zh) 2015-07-23 2020-12-11 武田药品工业株式会社 化合物及其作为ep4受体拮抗剂的用途
CN108473497B (zh) 2015-10-16 2021-09-10 卫材R&D 管理有限公司 Ep4拮抗剂

Also Published As

Publication number Publication date
PH12019502562A1 (en) 2020-07-20
US20230165859A1 (en) 2023-06-01
TW201900637A (zh) 2019-01-01
PH12019502562B1 (en) 2024-06-14
EP3625224B1 (en) 2021-08-04
HUE056406T2 (hu) 2022-02-28
UA124748C2 (uk) 2021-11-10
JP7065117B2 (ja) 2022-05-11
AU2018269667A1 (en) 2019-10-24
MA49127A (fr) 2021-05-26
CL2019003257A1 (es) 2020-03-27
LT3625224T (lt) 2021-10-25
WO2018210995A1 (en) 2018-11-22
CY1124528T1 (el) 2022-07-22
AR111806A1 (es) 2019-08-21
HRP20211532T1 (hr) 2022-01-07
TWI768043B (zh) 2022-06-21
MX2019013639A (es) 2020-01-21
SI3625224T1 (sl) 2021-11-30
IL270616B (en) 2022-01-01
PL3625224T3 (pl) 2022-01-10
EA039630B1 (ru) 2022-02-18
JP2020520359A (ja) 2020-07-09
ES2894124T3 (es) 2022-02-11
DK3625224T3 (da) 2021-11-08
CO2019010804A2 (es) 2019-10-09
EA201992679A1 (ru) 2020-05-06
MX394108B (es) 2025-03-21
KR102650756B1 (ko) 2024-03-22
CA3063637A1 (en) 2018-11-22
PE20191787A1 (es) 2019-12-24
CN110621666A (zh) 2019-12-27
RS62441B1 (sr) 2021-11-30
US20200069686A1 (en) 2020-03-05
CR20190567A (es) 2020-02-10
PT3625224T (pt) 2021-10-06
BR112019024114A2 (pt) 2020-06-02
AU2018269667B2 (en) 2022-02-03
KR20200006589A (ko) 2020-01-20
SG11201908660RA (en) 2019-10-30
EP3625224A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
MA49127B1 (fr) Dérivés d'indole n-substitués
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
TN2009000450A1 (fr) Derives de pyridine
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA32965B1 (fr) Derives de sulfonamides
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TNSN07022A1 (fr) Derives de pyridine
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA29926B1 (fr) Derives de pyrazine
MA49126B1 (fr) Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA51558B1 (fr) Dérivés de 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés similaires en tant que modulateurs du récepteur c5a pour le traitement de la vascularité et de maladies inflammatoires
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines